Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
| Autor: | Antonio Brunetti, Daniela Foti, Luigi Puccio, Stefania Giuliano, Eusebio Chiefari, Francesco Saverio Brunetti, Biagio Arcidiacono, Maria Mirabelli, Patrizia Caroleo, Sinan Tanyolaç, Domenica Maria Corigliano |
|---|---|
| Přispěvatelé: | Tıp Fakültesi |
| Rok vydání: | 2019 |
| Předmět: |
Male
endocrine system medicine.medical_specialty endocrine system diseases Health Toxicology and Mutagenesis lcsh:Medicine 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Overweight Article 03 medical and health sciences 0302 clinical medicine Weight loss Internal medicine Weight management medicine Humans Hypoglycemic Agents Retrospective Studies Glycemic Glycated Hemoglobin liraglutide medicine.diagnostic_test business.industry Liraglutide Body Weight lcsh:R Public Health Environmental and Occupational Health nutritional and metabolic diseases Middle Aged medicine.disease weight management Diabetes Mellitus Type 2 gender difference Female type 2 diabetes medicine.symptom Lipid profile business Body mass index medicine.drug |
| Zdroj: | International Journal of Environmental Research and Public Health, Vol 17, Iss 1, p 207 (2019) International Journal of Environmental Research and Public Health Volume 17 Issue 1 |
| ISSN: | 1660-4601 |
| Popis: | Background: Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naï ve to GLP-1 RAs. Patients and Methods: Forty overweight or obese patients treated with Liraglutide at doses up to 1.8 mg/day, in combination with one or more oral antidiabetic agents, were retrospectively assessed at baseline, during, and after 60 months of continuous therapy. Results: After 5 years of Liraglutide treatment, body weight decreased from 92.1 ± 20.5 kg to 87.3 ± 20.0 Kg (p < 0.001), with a mean reduction of 5.0 ± 7.0 Kg and a body mass index (BMI) decrement of &minus 2.0 ± 3.1 Kg/m2. On Spearman&rsquo s univariate analysis, change in body weight was correlated with female gender and baseline BMI. Hemoglobin A1c (HbA1c) decreased from 7.9 ± 0.9% at baseline to 7.0 ± 0.7% at the end of the study period (p < 0.001), followed by a significant reduction in fasting plasma glucose. No significant differences emerged in other biochemical parameters, despite a trend toward improvement in lipid profile. Notwithstanding encouraging effects on several markers of cardiovascular disease (CVD), increments in the 5- and 10-year risk for the first atherosclerotic cardiovascular event were documented, as four incident cases of myocardial infarction. Conclusions: Prolonging treatment with Liraglutide can lead to durable benefits in relation to weight and glycemic control, with a greater impact on women. These results extend and corroborate previous observations, suggesting that gender per se may modulate the response to Liraglutide. Despite favorable effects on some established CVD risks factors, the long-term role of Liraglutide in primary prevention of CVD in patients with T2D remains controversial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|